Skip to Main Content

In a bid to lower prescription drug costs, a federal agency is recommending pharmaceutical companies pay higher Medicaid rebates if they have not completed required trials to confirm the effectiveness of medicines that received accelerated approval.

Specifically, the Medicaid and CHIP Payment and Access Commission, or MACPAC, on Friday voted 16-to-1 to boost two different types of rebates that drug makers would have to offer Medicaid if they fail to complete so-called confirmatory trials. Although Congress has to act on the recommendation, the agency hopes that drug makers will be moved to complete these trials rather than take a hit on revenue.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!